|
STYX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.58219995280729E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.79840000014542E-07 |
| Normal-vs-Stage2 |
1.88849999971374E-07 |
| Normal-vs-Stage3 |
4.99039999990458E-07 |
| Normal-vs-Stage4 |
1.47159999741575E-08 |
| Stage1-vs-Stage2 |
1.107980E-01 |
| Stage1-vs-Stage3 |
2.716000E-01 |
| Stage1-vs-Stage4 |
3.064100E-02 |
| Stage2-vs-Stage3 |
4.980800E-01 |
| Stage2-vs-Stage4 |
6.410200E-01 |
| Stage3-vs-Stage4 |
2.439800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.0020999996474E-07 |
| Normal-vs-AfricanAmerican |
4.797600E-04 |
| Normal-vs-Asian |
3.50019999995066E-06 |
| Caucasian-vs-AfricanAmerican |
8.945800E-01 |
| Caucasian-vs-Asian |
6.186000E-01 |
| AfricanAmerican-vs-Asian |
8.079400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.95070000047681E-08 |
| Normal-vs-Female |
2.50849999661185E-08 |
| Male-vs-Female |
4.635200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.027480E-04 |
| Normal-vs-Age(41-60Yrs) |
7.16899872799104E-11 |
| Normal-vs-Age(61-80Yrs) |
5.69200000466452E-08 |
| Normal-vs-Age(81-100Yrs) |
5.779600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.576800E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.940230E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.674600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.760000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.065400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.769600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.699200E-01 |
| Classical-VS-Follicular |
3.99319999999648E-05 |
| Classical-VS-Other |
3.132800E-01 |
| Classical-VS-Normal |
8.88600000026329E-07 |
| Tall-VS-Follicular |
2.221700E-02 |
| Tall-VS-Other |
4.228000E-01 |
| Tall-VS-Normal |
4.602300E-03 |
| Follicular-VS-Other |
7.243600E-01 |
| Follicular-VS-Normal |
9.75679537162932E-11 |
| Other-VS-Normal |
9.503400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.8466008983894E-11 |
| Normal-vs-N1 |
1.90299999980326E-07 |
| N0-vs-N1 |
8.607000E-01 |
|
|
